Leerink Partnrs Issues Positive Estimate for Opthea Earnings

Opthea Limited (NASDAQ:OPT) – Analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Opthea in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($1.15) for the year, up from their prior estimate of ($1.20). The consensus estimate for Opthea’s current full-year earnings is ($1.40) per share. Leerink Partnrs also issued estimates for Opthea’s FY2026 earnings at ($1.05) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $1.60 EPS.

Separately, HC Wainwright decreased their target price on shares of Opthea from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.

Opthea Stock Down 0.8 %

Shares of OPT stock opened at $4.99 on Friday. Opthea has a 1 year low of $1.60 and a 1 year high of $5.45. The stock’s 50-day moving average is $3.61 and its two-hundred day moving average is $3.06.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.